Dry Eye

Knowing the shared signs and symptoms can lead to proper diagnosis.

The videos provide an overview of the report, review the diagnostic methodology section, and highlight key points from the management and therapy report.

The launch is supported by results from a phase 3 randomized, double-masked, placebo-controlled trial (3-02).

Several presentations at ASCRS 2026 spotlight faster dry eye relief and smarter pre-operative care, showing lifitegrast and new drugs can ease symptoms quickly and improve cataract biometry.

The study demonstrates that Corynebacterium mastitidis, a bacterium that resides on the ocular surface, can be genetically modified to secrete the anti-inflammatory cytokine interleukin-10.

The study was carried out between July 8 and August 1, 2024, and included 127 eyes from 68 children aged 8–14 years.

Previously, the company received CRLs from the FDA in April 2025 and November 2023 for NDAs for reproxalap for the treatment of dry eye.

The planned study will assess the safety, efficacy, and optimal dosing of the investigational therapy in approximately 150 patients with DED.

Examining the physiologic limits and patient selection for warm compress therapy in meibomian gland dysfunction can help identify when its usage may be ineffective.

The study highlights the broader impact of OR on patients’ quality of life.

Amniotic membrane therapy has been used in refractory cases to protect the ocular surface, modulate inflammation and fibrosis, and promote epithelial healing.

The review notes aesthetic considerations are increasingly important as social media and video conferencing spotlight facial appearance.

Clocking in for Workplace Eye Wellness Month means knowing the environmental factors contributing to a patient's dry eye.

Rachon, OD, FAAO, DipABO, details her SECO 2026 poster presentation, "Treatment of Stage 1 NK Secondary to Acoustic Neuroma Removal with Cryopreserved Amniotic Membrane."

According to a VSP Vision Care news release, 71% say they experience performance impacts due to screen-related visual discomfort, equating to nearly one full workday of lost productivity each week.

Tonk, MD, MBA, references updates from TFOS DEWS III that promote standardized screening tools.

Improved guidance on preservatives and allergens needed to ensure safety.

Key clinical trial data and PDUFA dates in early 2026 focus on treatments for dry eye, age-related macular degeneration, and rare eye diseases.

Telomere biology may link ocular aging and tissue dysfunction in the eye.

New drugs on the market and survey findings were among some of the top stories in dry eye from the past year.

Aldeyra met with the FDA on December 12, 2025, in which the FDA requested the company submit the CSR from the reproxalap dry eye disease field trial to the NDA.

The eye care providers authored an opinion article that has been published in "The Ocular Surface."

HUC1-394 is a peptide-based eye drop for dry eyes being developed by the company.

This year's conference brought eye care professionals insights, tips, and pearls.

Researchers performed a secondary analysis of the DREAM study data.